UBS

UBS Group
D

UBS

Arincen57/100B

UBS Group stock forecast 2027–2029

Analysts' average 12-month price target for UBS Group is 23.57, 50.7% below the current price of 47.77. Their targets range from 19.24 to 34.00.

Of the 2 firms that rated UBS Group in the past 12 months, 1 rate it buy or strong buy, 1 hold and 0 sell or strong sell (each firm at its latest rating): a Hold consensus.

12-month price target
23.57 USD
-50.65%

Analysts' 1-year price targets range from 19.24 to 34.00, with an average of 23.57.

Past year
1-year forecast
Strong sellStrong buy
Hold
2 ratings
Buy
1
Hold
1
Sell
0

12-month price target

Highest target34.00
Average target23.57
Lowest target19.24
Current price47.77

UBS Group price target history

See how analysts moved their price target

How analysts rate UBS Group, month by month

1 of 2 firms rate it buy now, against 3 of 3 in December 2025.

Buy Hold Sell

Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.

Month endBuyHoldSellFirms
Nov 20261102
Oct 20261102
Sept 20261102
Aug 20261102
Jul 20261102
Jun 20261102
May 20262103
Apr 20262103
Mar 20262002
Feb 20262002
Jan 20262002
Dec 20253003

UBS Group analyst upgrades, downgrades and price targets

The latest rating change came on 20 April 2026, when Barclays upgraded UBS Group from Underweight to Equal Weight.

DateFirmRatingPrice targetChangePrice then
20 Apr 2026
Barclays
Upgraded · Underweight → Equal Weight———
16 Dec 2025
B of A Securities
Upgraded · Neutral → Buy———

UBS Group EPS and revenue estimates

Analysts expect UBS Group's EPS to grow 33.9% a year until 2027, faster than over the last 5 years (5.9% a year) and the last 3 years (1.6%).

Analysts expect UBS Group's revenue to fall 8.3% a year until 2028. Over the last 5 years it grew 18.2% a year, and over the last 3 years it grew 26.1%.

Revenue

ReportedEstimate

EPS

ReportedEstimate
Fiscal yearEPSEPS growthEPS rangeRevenueRevenue growthRevenue rangeAnalysts
FY2027 (est.) 4.23+79.2%4.16 – 4.31 54.87B+14.7%54.69B – 55.22B3
FY2025 2.36+55.3%— 47.85B+2.7%——
FY2024 1.52—— 46.60B+15.3%——
FY2023 -0.03-101.3%— 40.40B+16.9%——
FY2022 2.24—— 34.55B———

Does UBS Group beat earnings estimates?

On average, analysts' EPS estimate was 38.0% off the result, either way, and their revenue estimate 2.6%, over the last 12 quarters.

EPS beats
38 / 74
Revenue beats
54 / 72
Average EPS surprise, last 12
+2.6%
Since
February 2007
QuarterReport dateEPS estimateReported EPSSurpriseRevenue estimateReported revenueSurprise
Q3 FY202628 Oct 20260.910.85-6.6%13.07B13.39B+2.4%
Q2 FY202629 Jul 20260.900.87-3.3%13.40B13.35B-0.4%
Q1 FY202629 Apr 20260.850.94+10.6%13.16B13.64B+3.7%
Q4 FY20254 Feb 20260.540.37-31.7%11.71B12.20B+4.2%
Q3 FY202529 Oct 20250.490.76+55.9%11.92B12.20B+2.3%
Q2 FY202530 Jul 20250.700.72+2.9%11.57B11.55B-0.2%
Q1 FY202530 Apr 20250.420.51+21.4%11.66B11.90B+2.1%
Q4 FY20244 Feb 20250.310.23-25.8%11.17B11.06B-1.0%
Q3 FY202430 Oct 20240.350.43+22.9%11.26B11.67B+3.6%
Q2 FY202414 Aug 20240.300.34+13.3%11.11B11.90B+7.2%
Q1 FY20247 May 20240.240.52+116.7%12.08B11.96B-1.0%
Q4 FY20236 Feb 20240.20-0.09-145.0%10.76B10.42B-3.1%

UBS Group stock price 2027–2029: scenarios

If UBS Group's earnings grow at the 33.9% a year analysts expect to FY2027, then 15.0% a year, it would earn about 5.59 a share in FY2029. At the P/E it has traded at over the last five years (3.7 to 19.1) that is 20.83 to 106.68 a share, or 68.92 at its average P/E of 12.3. This is arithmetic on the analysts' estimates, not a prediction.

Bull Base Bear
Fiscal yearEPSBearBaseBull
FY2027 4.2315.7552.1180.66
FY2028 (extrapolated)4.8618.1159.9392.76
FY2029 (extrapolated)5.5920.8368.92106.68

Each year's EPS is the analysts' consensus to FY2027; the years after grow 15.0% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (3.7, 12.3, 19.1).

Is UBS Group stock undervalued or overvalued?

UBS Group's P/E of 16.0 is around the middle of its 5-year range (3.0 to 54.5, median 17.2). It is in line with its own history. Buyers pay less for each point of growth than usual: a PEG of 0.5 on expected growth against 2.9 on its median P/E and past five years' growth. Fair value is not a reliable guide for UBS Group: its earnings swing (EPS fell ⁦81.7%⁩ in FY2024), so its usual P/E would mislead. Its forward P/E, on the consensus for FY2026, is 13.0.

Price to earnings ratio (TTM)
15.97
Five-year median P/E
17.20
Five-year P/E range
3.0 – 54.5
Forward P/E (FY2026)
12.99
PEG ratio
0.47
To the average target
-50.7%
See the full P/E history check Plus

Most undervalued US stocks

StockPriceFair valueUpside
99.090
194.93146Price 99.09244
+96.7%
42.225
82.9546Price 42.23165
+96.4%
186.680
360.82271Price 186.68451
+93.3%
213.670
405.57304Price 213.67507
+89.8%
161.160
305.51157Price 161.16396
+89.6%
160.650
300.09225Price 160.65375
+86.8%
165.860
308.95212Price 165.86442
+86.3%

Furthest below the fair value on each stock's page, updated every day.

Common questions about the UBS Group stock forecast

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.